BRAF protein
Daiichi Sankyo gains rights to potential blockbuster cancer drug
March 2, 2011Research and Development BRAF protein, Daiichi Sankyo, PLX4032, Plexxikon, melanoma, personalised medicine
Daiichi Sankyo has purchased US-based discovery firm Plexxikon for $805 million, gaining access to its potential blockbuster melanoma drug PLX4032. …
Roche weathers tough year and looks to pipeline for 2011
February 3, 2011Research and Development, Sales and Marketing 2010 pharma results, BRAF protein, GDC-0449, RG3616, RG7204, Roche, avastin, pertuzumab
Roche is looking to its innovative late-stage pipeline to help it get back on track for the next financial year …
Roche’s melanoma candidate impresses in phase II trials
November 5, 2010Research and Development BRAF protein, Cancer, Phase II, Plexxikon, RG7204, Roche
Roche’s mid-stage melanoma candidate has produced positive results in a difficult to treat cancer. RG7204 is an investigational, first-in-class molecule …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
August 14, 2026
